CLVT 最新10-Q变化
将 CLVT 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-11-03 与上一份 10-Q · 2026-07-29
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +46 | −45 | ~49 | 102 |
| 市场风险(第3项) | 文字有新增/删除 | 0 | 0 | ~3 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~15 | 0 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
| 其他信息 | 文字有新增/删除 | +7 | −3 | 0 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):法律诉讼
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-11-03
offer intelligence solutions, workflow solutions, and tech-enabled services to customers in the Academia & Government
(“A&G”) and Intellectual Property (“IP”) end markets, which form the basis of our reportable segment structure.
During the third quarter of 2026, we entered into a definitive commercial agreement to sell our Life Sciences & Healthcare
(“LS&H”) segment and concluded that the criteria for held-for-sale classification and discontinued operations presentation
were met as of September 30, 2026. Accordingly, the operating results of the LS&H segment have been reported as
相对上期删除的文字 · 来源:10-Q · 2026-07-29
by harnessing the power of human ingenuity. From research and learning to commercialization, we offer intelligence
solutions, workflow solutions, and tech-enabled services to customers in the Academia & Government (“A&G”), Intellectual
Property (“IP”), and Life Sciences & Healthcare (“LS&H”) end markets, which form the basis of our reportable segment
In July 2026, we announced that we entered into a definitive agreement to sell the LS&H business. We anticipate that the
transaction will close by the end of 2026, subject to customary closing conditions, including regulatory approvals and the
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-11-03
On August 7, 2026, Bar Veinstein, President, Academia & Government, entered into a trading plan intended to satisfy the
affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The trading plan provides for the sale of an
aggregate of up to 254,558 ordinary shares of the Company held by Mr. Veinstein. The trading plan terminates on the earlier
of the date all the shares covered by the trading plan are sold and December 7, 2026.
On October 30, 2026, Saurabh Saha notified the Company of his resignation from the Board of Directors of the Company,
相对上期删除的文字 · 来源:10-Q · 2026-07-29
During the quarter ended June 30, 2026, no director or officer (as defined in Rule 16a-1 under the Exchange Act) of the
Company adopted or terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement
(as such terms are defined in Item 408(a) of Regulation S-K).
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议